EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Hydroxyurea for nontransfusion-dependent β-thalassemia

Ali H Algiraigri, Nicola A M Wright, Elizabeth Oddone Paolucci, Aliya Kassam

Hematology/Oncology and Stem Cell Therapy · 2017-07 · 10 (3) · 116-125

DOI: 10.1016/j.hemonc.2017.02.002 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2017-07. Verfasst von Ali H Algiraigri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, King Abdulaziz University Hospital, Jeddah, Saudi Arabia; King Faisal Special Hospital and Research Center, Jeddah, Saudi A…. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective/background: Nontransfusion-dependent β-thalassemia (NTDβT) syndromes consist of β-thalassemia intermedia and moderate hemoglobin E/β thalassemias. They are characterized by varying degrees of chronic anemia and a wide spectrum of complications due to ineffective erythropoiesis and iron overload from chronic transfusions. Hydroxyurea (HU), an oral chemotherapeutic drug, is anticipated to decrease disease severity.

Methods

We performed a meta-analysis to evaluate the clinical efficacy and safety of HU in NTDβT patients of any age. MEDLINE, EMBASE, Cochrane databases, and major conference proceedings for studies that assessed HU in NTDβT patients were searched. Qualities of eligible studies were assessed by National Institutes of Health tools.

Results

Seventeen studies, collectively involving 709 patients, fulfilled the eligibility criteria. HU was associated with a significant decrease in transfusion need in severe NTDβT with complete and overall (≥50%) response rates of 42% and 79%, respectively. For mild NTDβT, HU was effective in raising hemoglobin by 1 g/L in 64% of patients.

Conclusion

HU appears to be effective, well tolerated, and associated with mild and transient adverse events. NTDβT patients may benefit from a trial of HU, although large randomized clinical trials assessing its efficacy should be conducted to confirm the findings of this metaanalysis and to assess its long-term toxicity and response sustainability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdolescentAdultBlood TransfusionChildChild, PreschoolHumansHydroxyureaMiddle AgedYoung Adultbeta-Thalassemia

Stichwörter der Autor:innen

Blood transfusionHydroxyureaMeta-analysisNon-transfusion dependent β-thalassemiaβ-thalassemia intermedia

Substanzen

Hydroxyurea

Autor:innen und Institutionen

  • Department of Hematology, King Abdulaziz University Hospital, Jeddah, Saudi Arabia; King Faisal Special Hospital and Research Center, Jeddah, Saudi Arabia; Department of Community Health Science, University of Calgary,…
  • Department of Pediatrics, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Department of Community Health Science, University of Calgary, Calgary, Alberta, Canada.

Zitieren

APA

Algiraigri, A. H., Wright, N. A. M., Paolucci, E. O., & Kassam, A. (2017). Hydroxyurea for nontransfusion-dependent β-thalassemia. Hematology/Oncology and Stem Cell Therapy, 10(3), 116-125. https://doi.org/10.1016/j.hemonc.2017.02.002

Vancouver

Algiraigri AH, Wright NAM, Paolucci EO, Kassam A. Hydroxyurea for nontransfusion-dependent β-thalassemia. Hematology/Oncology and Stem Cell Therapy. 2017;10(3):116-125. doi:10.1016/j.hemonc.2017.02.002

BibTeX
@article{Algiraigri2017,
  author = {Algiraigri, Ali H and Wright, Nicola A M and Paolucci, Elizabeth Oddone and Kassam, Aliya},
  title = {Hydroxyurea for nontransfusion-dependent β-thalassemia},
  journal = {Hematology/Oncology and Stem Cell Therapy},
  year = {2017},
  volume = {10},
  number = {3},
  pages = {116--125},
  doi = {10.1016/j.hemonc.2017.02.002}
}
Kostenlos starten →